Compare Adaptive Biotechnologies Corp (ADPT) vs Plug Power Inc (PLUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Plug Power Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.99 (market cap $3.33B), while Plug Power Inc trades at $2.43 (market cap $3.46B). The key difference: Adaptive Biotechnologies Corp and Plug Power Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | PLUG | |
|---|---|---|
Market Cap | $3.33B | $3.46B |
Sector | Health | Industrials |
52-Week High | $22.37 | $4.14 |
52-Week Low | $10.24 | $1.40 |
Enterprise Value | $3.19B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Plug Power (PLUG) trades at $2.48, down 6.06% today amid sector-wide profit-taking, despite recent operational milestones. The stock shows a bearish technical signal with key resistance at $3.00. Fundamentally, the company reported a net loss of $1.63 billion in 2025 with negative gross and net margins, though it has beaten EPS estimates for three consecutive quarters. Revenue grew to $709.92 million in 2025 from $629 million in 2024, but cash flow remains negative, requiring financing to cover operations.
The outlook is high-risk with a path to profitability projected by 2028, but consistent losses and high cash burn pose significant challenges. Analyst consensus is mixed with a $3.28 price target, offering potential upside, yet investors face substantial execution and funding risks. The stock's viability hinges on successful scaling of hydrogen projects and achieving positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
